Xconomy | Boston - Business + Technology in the Exponential Economy

With a $25 Million Bankroll and Technology “Fully Baked” by Biogen Idec, Stromedix is Heading into the Uncharted Territory of Fibrosis
Trubion Wins Patent Dispute With Genentech, Biogen Idec
Stromedix Drug Gets Orphan Status
Follica’s Fortunes Growing, Icahn’s Biogen Holdings Mounting, Genzyme’s Mipomersen Work Progressing, & More Life Sciences News
GSK Takes Sirtris and Taps Alnylam Venture, FDA Deals Genzyme Drug a Blow, Resolvyx Finances Fish-Oil Drugs, & More Life Sciences News

Stromedix Wins Patent For Lead Drug

Stromedix, a Cambridge, MA-based biotech company, said it has received a U.S. patent that protects its lead drug for fibrosis, STX-100. The patent, U.S. 7,465,449, covers high-affinity monoclonal antibodies and antigen-binding fragments that block a target on cells that is an important regulator of fibrosis and tissue injury. Rebecca described this technology that Stromedix acquired from Biogen Idec back in April.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: